Codon-Modified IL-1Ra Gene Delivery for Osteoarthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in achieving and maintaining effective concentrations of IL-1Ra in joints for treating osteoarthritis, as conventional drug delivery methods struggle to sustain therapeutically relevant levels over time.
Innovation Solution
Development of codon-modified genes encoding IL-1Ra, specifically equine and human IL-1Ra, which are delivered via recombinant adeno-associated virus (rAAV) particles, leading to sustained expression and secretion of IL-1Ra in synovial fluid, leveraging a Kozak sequence for enhanced expression and a cytomegalovirus promoter for disease-controlled expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional drug delivery methods are used to administer IL-1Ra intra-articularly, then the therapeutic can be delivered to the joint, but effective concentrations cannot be maintained over time
Solution Approach 1:
The patent uses a viral vector (AAV) as an intermediary carrier to deliver the IL-1Ra gene to joint cells. This mediator enables sustained protein production by introducing genetic material that expresses the therapeutic protein continuously, rather than requiring repeated administration of the protein itself.
Solution Approach 2:
The patent replaces the mechanical approach of repeatedly injecting IL-1Ra protein with a genetic approach. By delivering the gene encoding IL-1Ra, the system substitutes continuous mechanical intervention with a self-sustaining biological production mechanism within host cells.
2Quantity of substance
If repeated application of IL-1Ra protein is used, then therapeutic concentrations can be achieved, but the complexity and burden of treatment increases
Solution Approach 1:
The gene therapy system enables the joint tissue to produce IL-1Ra autonomously once the viral vector has delivered the gene. The host cells' biosynthetic machinery is harnessed to continuously produce the therapeutic protein, eliminating the need for repeated external applications.
Solution Approach 2:
The viral vector establishes a permanent or long-lasting expression system that continuously produces IL-1Ra. This ensures uninterrupted therapeutic action without requiring periodic re-administration, providing sustained concentration over time.
3Quantity of substance
If high levels of IL-1Ra are produced in diseased joints, then therapeutic efficacy is improved, but systemic immunogenicity may increase
Solution Approach 1:
The viral vector is designed with tropism for joint tissue, delivering the gene specifically to cells within the joint capsule and synovium. This localized delivery ensures that high levels of IL-1Ra are produced only at the site of disease, minimizing systemic exposure and associated immunogenic responses.
Solution Approach 2:
The AAV viral vector serves as a controlled intermediary that facilitates localized gene delivery. Its specific tropism for joint tissue acts as a natural filter, preventing widespread systemic distribution and thereby reducing the risk of systemic immunogenicity while maintaining high local therapeutic concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in significantly elevated IL-1Ra levels in synovial fluid, reducing lameness, joint effusion, and synovitis in equine OA models, with prolonged therapeutic effects and targeted delivery to diseased joints, minimizing systemic immunogenicity.
Implementation Method 1
delivering cDNA for IL-1Ra to cells resident in the joint tissues
Implementation Method 2
intra-articular delivery of the codon-modified eqIL-1Ra encoding gene
Implementation Method 3
The codon-modified eqIL-1Ra encoding gene provides higher levels of expression of eqIL-1Ra compared to the native or endogenous gene
Implementation Method 4
the biosynthetic machinery of the modified cells is directed to overproduce and continuously secrete transgenic IL-1Ra protein
Implementation Method 5
use of a Kozak sequence leader immediately upstream from the translation start site... The Kozak sequences further improve the expression level of human IL-1Ra (hIL-1Ra) or eqIL-1Ra in joints
Implementation Method 6
use of a cytomegalovirus promoter for disease-controlled expression
Implementation Method 7
transgene expression after treatment is much higher in diseased synovium, particularly so in regions with inflammation and synovitis, compared to normal or undiseased tissue
Implementation Method 8
the biosynthetic machinery of the modified cells is directed to overproduce and continuously secrete transgenic IL-1Ra protein into the synovial fluid
Implementation Method 9
raises the steady state levels of eqIL-1Ra in synovial fluid significantly, e.g., more than 100-fold over background for a period of at least 6 months
Data Source
AI summary
The present disclosure relates to compositions and methods for treatment of degenerative conditions of large weight-bearing joints, such as osteoarthritis, by intra-articular delivery of a codon-modified IL-1Ra encoding gene.